Haemonetics (HAE)
(Delayed Data from NYSE)
$78.16 USD
+3.18 (4.24%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $79.00 +0.84 (1.07%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$78.16 USD
+3.18 (4.24%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $79.00 +0.84 (1.07%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Alere (ALR) Appeals to Reinstate Medicare Billing Privilege
by Zacks Equity Research
Alere Inc. (ALR) announced that it has recently appealed at the Centers for Medicare & Medicaid Services for reinstatement of Medicare billing privilege.
NuVasive (NUVA) Wins MHLW Approval for XLIF Device Suite
by Zacks Equity Research
NuVasive (NUVA) recently announced the receipt of approval from MHLW, for instruments used in the eXtreme Lateral Interbody Fusion (XLIF) procedure.
LabCorp: Covance Drug Prospects Bright, Competition Rife
by Zacks Equity Research
On Dec 28, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH).
ResMed: SDB Business Faces Risks, Reimbursement a Drag
by Zacks Equity Research
On Dec 27, we issued an updated research report on San Diego, CA-based ResMed, Inc. (RMD).
Nutrisystem Declares Multi-Brand Marketing Approach for '17
by Zacks Equity Research
Nutrisystem Inc. (NTRI) announced that it will focus on a multi-brand marketing approach with two new distinct programs.
Myriad Genetics' Unit Releases Favorable Data on Vectra DA
by Zacks Equity Research
Myriad Genetics, Inc.'s (MYGN) subsidiary, Crescendo Bioscience released favorable data on the use of Vectra DA to predict treatment response in patients with rheumatoid arthritis (RA).
Cardiovascular Systems (CSII): Q1 Solid, Net Losses Linger
by Zacks Equity Research
On Dec 27, we issued an updated research report on St. Paul, MN-based Cardiovascular Systems, Inc. (CSII).
Haemonetics' Plasma Group Impresses, Blood Center a Drag
by Zacks Equity Research
On Dec 12, we issued an updated research report on Braintree, MA-based Haemonetics Corporation (HAE).
Haemonetics Introduces Upgraded NextGen DMS 4 Software
by Zacks Equity Research
Haemonetics Corporation (HAE) recently unveiled upgraded NextGen DMS (Donor Management System) to augment plasma collection center operations.